ArticleCancer medicine2024

Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma.

Wenjiao Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.